Home | Daily Musings | About Us | Contact Us |
Search the Site   Advanced Search »
Sections
Archive
Mo Tu We Th Fr Sa Su
12345
6789101112
13141516171819
20212223242526
2728293031




email Email to a friend | print Print version |

Merck Reverses Vioxx Course, Agrees to Settle

By Jake on November 09,2007

image

The pharmaceutical giant Merck reverses its course and agrees to settle Vioxx lawsuits. Merck will pay nearly $5 billion to settle nearly 27,000 pending lawsuits. Up until this time, the company's policy was to fight each suit individually, a strategy it was winning. But after spending an estimated $600 million a year in legal fees, Merck suits must have realized it wouldn't take long to exceed the settlement amount. Of course the real winners will be the lawyers. What else is new?

From The New York Times:

Three years after withdrawing its pain medication Vioxx from the market, Merck has agreed to pay $4.85 billion to settle 27,000 lawsuits by people who claim they or their family members suffered injury or died after taking the drug, according to two lawyers with direct knowledge of the matter.

The settlement, one of the largest ever in civil litigation, comes after nearly 20 Vioxx civil trials over the last two years from New Jersey to California. After losing a $253 million verdict in the first case, Merck has won most of the rest of the cases that reached juries, giving plaintiffs little choice but to settle.

The settlement will help put Vioxx behind Merck, as well as sharply reduce its Vioxx-related legal defense fees, which are now running at more than $600 million annually.

Judges in Louisiana, New Jersey and California, who oversee nearly all the lawsuits, had pressed for a deal before a new wave of trials was scheduled to begin in January.

The agreement could still collapse, though lawyers with knowledge of the deal said that was unlikely. The deal becomes binding only if 85 percent of all plaintiffs agree to drop their cases and take the deal.

Plaintiffs will receive different settlement payments depending on the severity of their injuries and the length of time they took Vioxx.

“We’ve been asked by the judge to talk to the plaintiffs and we are talking to them,” Kent Jarrell, a spokesman for Merck, said at 12:30 Friday morning. “Right now, there is no finalized agreement.”

Two lawyers with knowledge of the deal, however, confirmed it independently.

 


186 times read

Did you enjoy this article?

1 2 3 4 5 (total 0 votes)